Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 6 (February 20), 2008: pp. 856-862
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.13.5947

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heist, R. S.
Right arrow Articles by Christiani, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heist, R. S.
Right arrow Articles by Christiani, D. C.
Related Articles
Right arrowRelated Correspondence

VEGF Polymorphisms and Survival in Early-Stage Non–Small-Cell Lung Cancer

Rebecca Suk Heist, Rihong Zhai, Geoffrey Liu, Wei Zhou, Xihong Lin, Li Su, Kofi Asomaning, Thomas J. Lynch, John C. Wain, David C. Christiani

From the Massachusetts General Hospital; Harvard School of Public Health, Boston, MA; Princess Margaret Hospital, Toronto, Ontario, Canada

Corresponding author: David C. Christiani, MD, MPH, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115; e-mail: dchris{at}hsph.harvard.edu

Purpose: Polymorphisms in the VEGF gene have been identified that are believed to have functional activity. We hypothesized that such polymorphisms may affect survival outcomes among early-stage non—small-cell lung cancer (NSCLC) patients.

Patients and Methods: We evaluated the relationship between VEGF polymorphisms and overall survival (OS) among patients with early-stage NSCLC treated with surgical resection at Massachusetts General Hospital from 1992 to 2001. We specifically investigated the VEGF polymorphisms +936C>T (rs3025039), –460T>C (rs833061), and +405G>C (rs2010963). Analyses of genotype associations with survival outcomes were performed using Cox proportional hazards models, Kaplan-Meier methods, and the log-rank test.

Results: There were 462 patients and 237 deaths. Patients carrying the variant C allele of the VEGF +405G>C polymorphism had significantly improved survival (crude hazard ratio [HR] = 0.70; 95% CI, 0.54 to 0.90; P = .006; adjusted HR = 0.70; 95% CI, 0.54 to 0.91; P = .008). Five-year OS for patients carrying the variant C allele of the VEGF +405G>C polymorphism was 61% (95% CI, 54% to 67%) versus 51% (95% CI, 43% to 59%) for those who had the wild-type variant. There was a trend toward improved survival among patients carrying the variant T allele of the VEGF +936C>T polymorphism (crude HR = 0.74; 95% CI, 0.53 to 1.03; P = .07; adjusted HR = 0.73; 95% CI, 0.52 to 1.03; P = .07). Moreover, patients with higher number of variant alleles of the +405G>C and +936C>T polymorphisms had better survival. There was no association found with the –460T>C polymorphism.

Conclusion: Polymorphisms in VEGF may affect survival in early-stage lung cancer.

Supported by National Institutes of Health Grants No. CA074386 (D.C.C.), CA092824 (D.C.C.), CA090578 (D.C.C.), and K12CA087723 (R.S.H.), and the Flight Attendants Medical Research Institute Young Clinical Scientist Award (W.Z.).

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Correspondence

  • Vascular Endothelial Growth Factor Polymorphisms in Early-Stage Non–Small-Cell Lung Cancer
    Mehul Patel, Sikander Ailawadhi, Francisco Hernandez-Ilizaliturri, and Gregory E. Wilding
    JCO 2008 26: 3289-3290 [Full Text]


This article has been cited by other articles:


Home page
NEJMHome page
R. S. Herbst, J. V. Heymach, and S. M. Lippman
Lung Cancer
N. Engl. J. Med., September 25, 2008; 359(13): 1367 - 1380.
[Full Text] [PDF]


Home page
JCOHome page
R. S. Heist and D. C. Christiani
In Reply
J. Clin. Oncol., July 1, 2008; 26(19): 3290 - 3290.
[Full Text] [PDF]


Home page
JCOHome page
M. Patel, S. Ailawadhi, F. Hernandez-Ilizaliturri, and G. E. Wilding
Vascular Endothelial Growth Factor Polymorphisms in Early-Stage Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2008; 26(19): 3289 - 3290.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online